

A first result of the C-RAD/ Cyrpa merger

C-RAD AB with its three fully owned subsidiaries and three international sales companies are all active in the field of radiation therapy. Cyrpa is an innovative company specialized in radiation therapy. A first order by Abex Medical System Sdn Bhd in Malaysia of a Cyrpa HIT 3 system for virtual simulation has been booked. The system is interfaced to the C-RAD c4D platform.

In March 2013 the merger of Cyrpa and C-RAD was announced. The market and sales activities of the two companies have been integrated. The Cyrpa organization is responsible for sales of the entire program to South- and East Europe, Africa and South America. The C-RAD direct sales force is responsible for Scandinavia, German speaking countries, Asia and distributionship to designated markets. The North American market is at present being promoted by C-RAD Inc. and Cyrpa Americas respectively. The plan is to merge the two operations.

The integrated product program is interfaced to the C-RAD c4D platform. The solution for 4 DCT and virtual simulation will be released in July 2013.

The C-RAD/Cyrpa group will as the only vendor in the field offer complete programs of optical systems for use at the CT and in the linac room.

Erik Hedlund, CEO, C-RAD AB:

"We are happy to announce the first result of the integration of manufacturing, product program and marketing/ sales of the two companies. The process has been running smooth and with great enthusiasm of both groups.

By offering an integrated solution based on the c4D platform, the radiation therapy clinics have the opportunity to upgrade their systems with additional functionalities."

About Cyrpa:

CYRPA, established in 2010 in Belgium, is a company specialized in innovative solutions in the radiotherapy field.

Founded by technical experts and an innovation investment fund, CYRPA products are currently distributed in 22 countries on mainland Europe but also in the USA, Latin America, Africa and Asia.

In 2011 CYRPA launched its « HIT » product range (High Impact Technology): laser systems used for patient-positioning during virtual simulation and radiotherapy treatment. The HIT systems include two major innovations: double-diode for each laser line, and the SmartPhantom, a device that allows high precision automatic calibration of the laser system in the CT room. CYRPA is the only positioning laser manufacturer that guarantees an accuracy of 0.1mm.

CYRPA's aim is to offer quality solutions in radiotherapy that provide higher precision for the patient and more safety for the medical staff.

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems.



End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 24 people. The activities in C-RAD AB originate from research and development at the Karolinska Institute in Solna. Sales of the company's first product, the C-RAD Sentinel^{IM,} started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has acquired 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier. For more information on C-RAD, please visit www.c-rad.com.

For further information:

Erik Hedlund, CEO C-RAD AB, Phone +46-18-666931, E-mail erik.hedlund@c-rad.se